Effect of telmisartan on plasma apelin-12 in patients with essential hypertension

WU Zhe-bing,YU Jing,LI Guang-di,GUO Xue-ya,CHANG Peng,HE Da-yuan
DOI: https://doi.org/10.3969/j.issn.1004-583X.2006.21.004
2006-01-01
Abstract:Objective To investigate the effect of telmisartan on plasma apelin-12 as well as its clinical significance in essential hypertension(EH) patients. Methods The plasma levels of apelin-12 in mild and medium range EH (45 patients) and healthy control group (30 patients) were detected by enzyme linked immunosorbent assay. After 12 weeks’anti-hypertensine lowering with telmisartan for EH group, the above item was detected again. Utilizing ultrasonic cardiography(UCG) to determine heart function parameters, such as left ventricular ejection fraction(LVEF), left ventricular fraction shortening(LVFS), left ventricular diastolic dimension(LVDd), ejection fraction(EF) slope rate,E/A. Results The plasma apelin-12 level after treatment of telmisartan was significantly higher than that of treatment before ( 3.14 ± 0.40 ) μg/L vs ( 3.41 ± 0.59 ) μg/L ( P = 0.013 ). The plasma apelin-12 level before treatment was significantly lower than that in healthy control group ( 3.14 ± 0.40 ) μg/L vs ( 3.61 ± 0.30 ) μg/L ( P = 0.0001 ). Heart function parameters were not obvious changed( P > 0.05 ). Conclusion The levels of plasma apelin-12 in mild and medium range EH were degraded, and inverse correlation to mean arterial pressure(MAP)( r = -0.410 , P = 0.005 ). This result demonstrated that the variation of plasma apelin-12 has some significance to pathogenesy of EH, and telmisartan could heighten the levels of plasma apelin-12 in mild and midium range EH. The anti-hypertensive role of telmisartan is related to plasma apelin-12. Telmisartan does not influence heart function of mild and medium range EH.
What problem does this paper attempt to address?